VYNE Company Profile and Key Details

VYNE Therapeutics Inc. has 25.47 million shares outstanding. The public float is 23.23 million shares, elevated short interest at 5.28% of float. This equals 1.34 million shares. The short ratio is 0.34 days. Institutional investors hold 14.69% of the float. Insiders own 4.33%. PERCEPTIVE ADVISORS LLC holds 4.94 million shares, Remeditex Ventures LLC has 1.58 million shares and Domzalski David has 1.32 million shares.

VYNE Therapeutics Inc. generated EPS of -$0.79 over the past year. Five-year average earnings growth is 65.87%. Wall Street analysts project EPS growth of 11.71% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.23. Next year's EPS is expected at $25.91. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.75 to $5.75. The high target offers 908.77% upside. The low target suggests 908.77% downside. The mean target is $5.75. This offers 908.77% upside. VYNE Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -10.36%. The prior quarter beat by -43.48%. Over the last six quarters, Apple has recorded several small beats. These include 15.79% in August 14, 2024.

VYNE Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.44. This means the shares are trading above this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.28 and $3.40. With a market capitalization of about $9.49 million, VYNE Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.96). Key stats such as the average daily volume over the past year has been around 5.78 million shares, volume is running light vs its 52-week average. Headquartered in Bridgewater, NJ, VYNE Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David T. Domzalski, the company employs approximately 13 people and listed since January 25, 2018. VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.

VYNE Therapeutics Inc. trades at a P/E ratio of -0.72, slightly below the S&P 500 average, with a price-to-sales ratio of 18.12 and a price-to-book ratio of 0.76 suggesting the stock is closer to book value. The P/FCF stands at -0.25, also above market averages.

Our AI price prediction model suggests that VYNE Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.85%, with price expected at $0.66 by January 23, 2026, within a range of $0.60 to $0.73 3-Month Outlook: Projected fall of -50.85%, reaching $0.28 by April 09, 2026, with a range of $0.20 to $0.35. 1-Year Outlook: Projected loss of -85.96%, with price at $0.08 by December 31, 2026, within a range of $0.00 to $0.00.

VYNE Therapeutics Inc. (NASDAQ:VYNE) shares are flat -1.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows VYNE Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.07, suggesting 1843.13% upside. Our AI forecast model points to short-term strength (15.85% over two weeks), a medium-term fall (-50.85% over three months), and a longer-term loss (-85.96% over one year), with expected trading ranges indicating moderate volatility.